CN111247163B - 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 - Google Patents

渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 Download PDF

Info

Publication number
CN111247163B
CN111247163B CN201880068213.4A CN201880068213A CN111247163B CN 111247163 B CN111247163 B CN 111247163B CN 201880068213 A CN201880068213 A CN 201880068213A CN 111247163 B CN111247163 B CN 111247163B
Authority
CN
China
Prior art keywords
receptor
rage
gpcrs
activation
certain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880068213.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111247163A (zh
Inventor
K·D·G·普莱杰
M·C·托马斯
R·J·皮克林
C·罗萨多
C·蒂凯利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Monash University
Original Assignee
University of Western Australia
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017903381A external-priority patent/AU2017903381A0/en
Application filed by University of Western Australia, Monash University filed Critical University of Western Australia
Priority to CN202411603566.3A priority Critical patent/CN120607606A/zh
Publication of CN111247163A publication Critical patent/CN111247163A/zh
Application granted granted Critical
Publication of CN111247163B publication Critical patent/CN111247163B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201880068213.4A 2017-08-22 2018-08-21 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 Active CN111247163B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411603566.3A CN120607606A (zh) 2017-08-22 2018-08-21 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017903381A AU2017903381A0 (en) 2017-08-22 Screening Assays, Modulators and Modulation of Activation of Receptor For Advanced Glycation End-Products (RAGE)
AU2017903381 2017-08-22
AU2018902298 2018-06-26
AU2018902298A AU2018902298A0 (en) 2018-06-26 Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE)
PCT/AU2018/050883 WO2019036753A1 (en) 2017-08-22 2018-08-21 SCREENING TESTS, MODULATORS AND MODULATION OF RECEIVER ACTIVATION FOR ADVANCED GLYCATION TERMINAL PRODUCTS (RAGE)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411603566.3A Division CN120607606A (zh) 2017-08-22 2018-08-21 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节

Publications (2)

Publication Number Publication Date
CN111247163A CN111247163A (zh) 2020-06-05
CN111247163B true CN111247163B (zh) 2024-11-26

Family

ID=65438276

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411603566.3A Pending CN120607606A (zh) 2017-08-22 2018-08-21 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节
CN201880068213.4A Active CN111247163B (zh) 2017-08-22 2018-08-21 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202411603566.3A Pending CN120607606A (zh) 2017-08-22 2018-08-21 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节

Country Status (7)

Country Link
US (2) US12060408B2 (enExample)
EP (1) EP3672982A4 (enExample)
JP (2) JP2020531514A (enExample)
CN (2) CN120607606A (enExample)
AU (1) AU2018322482B2 (enExample)
CA (1) CA3109871A1 (enExample)
WO (1) WO2019036753A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018322482B2 (en) * 2017-08-22 2024-04-04 Monash University Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (RAGE)
KR102203850B1 (ko) * 2019-04-09 2021-01-18 사회복지법인 삼성생명공익재단 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법
EP4168548A1 (en) 2020-06-22 2023-04-26 Regeneron Pharmaceuticals, Inc. Treatment of obesity with g-protein coupled receptor 75 (gpr75) inhibitors
WO2022150709A1 (en) * 2021-01-11 2022-07-14 President And Fellows Of Harvard College Compositions and methods for treating viral infection
CN113293212A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用
CN113789379B (zh) * 2021-08-30 2022-08-23 远见生物科技（上海）有限公司 一种检测前列腺癌的诊断试剂盒及其检测方法与应用
JP2023084477A (ja) * 2021-12-07 2023-06-19 花王株式会社 硫黄化合物を原因とするにおいの抑制剤の評価及び／又は選択方法
KR20230147988A (ko) * 2022-04-15 2023-10-24 아주대학교산학협력단 Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물
WO2024044659A1 (en) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
CN118777620A (zh) * 2023-04-07 2024-10-15 浙江友宁生物医药科技有限公司 Gpr139受体激活检测方法、生理功能评价方法及应用
CN116410335B (zh) * 2023-04-24 2024-08-13 徐州医科大学 一种多肽tat-mrgprx1c及其应用
CN118755834B (zh) * 2024-07-15 2025-11-18 河北医科大学第四医院（河北省肿瘤医院） 胃癌复发预测模型
CN119901926A (zh) * 2025-03-31 2025-04-29 浙江省立同德医院(浙江省精神卫生研究院) 一种基于rage过表达和spr技术的rage靶向药物筛选方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007011411A (es) * 2005-03-17 2007-11-13 Univ Columbia Interaccion rage/diaphanous y composiciones relacionadas y metodos.
AU2018322482B2 (en) * 2017-08-22 2024-04-04 Monash University Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (RAGE)

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization.;Endy Widya等;《INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE》;20130809;第32卷;938-944 *
Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization;Endy Widya Putranto等;《INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE》;20130809;第32卷;938-944 *
Interaction of β1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling;Weizhong Zhu et al.;《JCI Insight》;20160121;第1卷(第1期);e84969 *
Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE) - and amyloid beta 1-42-induced signal transduction in glial cells;Alexander Slowik等;《Molecular Neurodegeneration》;20121120;第7卷;55 *
Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products (RAGE);Yokomizo等;《The FASEB Journal》;20160126;第30卷(第5期);1811-1822 *
Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction.;Michaele B等;《scientific reports》;20160303;第6卷;22450 *
The IKKα-Dependent NF-κB p52/RelB Noncanonical Pathway Is Essential To Sustain a CXCL12 Autocrine Loop in Cells Migrating in Response to HMGB1;Richard R. Kew et al.;《J Immunol》;20120301;第188卷(第5期);2380-2386 *

Also Published As

Publication number Publication date
AU2018322482B2 (en) 2024-04-04
EP3672982A4 (en) 2021-06-09
WO2019036753A1 (en) 2019-02-28
US20200207836A1 (en) 2020-07-02
US12060408B2 (en) 2024-08-13
AU2018322482A1 (en) 2020-04-02
CN120607606A (zh) 2025-09-09
EP3672982A1 (en) 2020-07-01
CN111247163A (zh) 2020-06-05
JP2020531514A (ja) 2020-11-05
US20250019415A1 (en) 2025-01-16
CA3109871A1 (en) 2019-02-28
JP2023156353A (ja) 2023-10-24

Similar Documents

Publication Publication Date Title
CN111247163B (zh) 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节
JP2018511329A (ja) Ｇｐｃｒアゴニストポリペプチドに関連する方法および組成物
Douchez et al. Design, synthesis, and biological assessment of biased allosteric modulation of the urotensin II receptor using achiral 1, 3, 4-Benzotriazepin-2-one turn mimics
Cook et al. Cleavage of the angiotensin II type 1 receptor and nuclear accumulation of the cytoplasmic carboxy-terminal fragment
Axén et al. Cyclic insulin‐regulated aminopeptidase (IRAP)/AT4 receptor ligands
Wei et al. Urotensin II Receptor Modulation with 1, 3, 4-Benzotriazepin-2-one Tetrapeptide Mimics
KR20010081109A (ko) 신규 ｇ 단백질 공액형 리셉터단백질, 그 ｄｎａ 및 그리간드
Deng et al. Structure–activity relationship of GPR15L peptide analogues and investigation of their interaction with the GPR15 receptor
Gleixner et al. [3H] UR-JG102–A Radiolabeled Cyclic Peptide with High Affinity and Excellent Selectivity for the Neuropeptide Y Y4 Receptor
DK2895189T3 (en) PEPTID ANTAGONISTS OF THE VASOPRESSIN-2 RECEPTOR
US20100056442A1 (en) Use of gpr101 receptor in methods to identify modulators of hypothalamic proopiomelanocortin (pomc)-derived biologically active peptide secretion useful in the treatment of pomc-derived biologically
Corbani et al. Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors
US20220169693A1 (en) Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules
JP2023517768A (ja) ＭＳ療法のためのκオピオイド受容体リガンドと組み合わしてのシクロチド
WO2001057524A1 (fr) Procede de criblage
WO2001040797A1 (fr) Procede de criblage
CN113811321B (zh) 新型选择性ackr3调节剂及其用途
Schulein et al. Functional significance of the signal peptides of corticotropin-releasing factor receptors
Alexander et al. Class A orphans in GtoPdb v. 2021.3
JP2005021151A (ja) スクリーニング方法
WO2004097411A1 (ja) 新規スクリーニング方法
WO2005121356A1 (ja) 新規スクリーニング方法
JP2001309792A (ja) スクリーニング方法
Fakhfouri Interventions pharmacologiques affectants spécifiquement la signalisation du récepteur D2 de la dopamine médiée par la beta arrestine 2
Grämer Development of a GRK2-inhibitory peptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant